文献速递脑血管病

那他珠单抗治疗急性缺血性卒中(ACTION II):随机安慰剂对照试验

Natalizumab in acute ischemic stroke (ACTION II): A randomized, placebo-controlled trial.
PubMed 文献 · Neurology · 2020-06-26

该双盲2b期试验纳入18-80岁、NIHSS 5-23分的急性缺血性卒中患者,随机接受单次静脉那他珠单抗300mg、600mg或安慰剂,主要终点为90天良好结局复合指标。结果显示那他珠单抗组良好结局可能性低于安慰剂组(OR 0.60,95%CI 0.39-0.93),按治疗时间窗或溶栓/取栓分层无效应修饰,不良事件、严重不良事件及死亡无差异。结论为急性缺血性卒中后24小时内给予那他珠单抗未改善患者结局。

要点

  • 那他珠单抗300或600mg组90天良好结局可能性低于安慰剂(OR 0.60,95%CI 0.39-0.93)。
  • 治疗时间窗(≤9或>9至≤24小时)及溶栓/取栓使用未见效应修饰。
  • 不良事件、严重不良事件及死亡发生率在组间无差异。

核心结论

  • 急性缺血性卒中后24小时内给予那他珠单抗未改善患者结局,良好结局可能性反而低于安慰剂。

研究设计与样本

  • 双盲2b期随机安慰剂对照试验,纳入美国及欧洲53个中心、18-80岁、NIHSS 5-23分的急性缺血性卒中患者。
  • 患者按1:1:1随机接受单次静脉那他珠单抗300mg、600mg或安慰剂,按治疗时间窗(≤9或>9至≤24小时)分层。
  • 主要终点为90天良好结局复合指标(改良Rankin量表≤1且Barthel指数≥95),在全部接受完整剂量患者中评估。
  • 样本量基于贝叶斯模型估算,未使用P值进行假设检验。

主要发现

  • 那他珠单抗300或600mg组良好结局可能性低于安慰剂组(OR 0.60,95%CI 0.39-0.93)。
  • 治疗时间或溶栓/取栓使用未见效应修饰。
  • 那他珠单抗300mg、600mg与安慰剂组不良事件发生率分别为90.0%、92.1%、92.3%。
  • 严重不良事件发生率分别为25.6%、32.6%、20.9%;死亡率分别为6.7%、4.5%、5.5%。

临床怎么用

  • 不推荐对急性缺血性卒中患者(发病≤24小时)使用那他珠单抗以改善功能结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We evaluated the effect of 2 doses of natalizumab on functional outcomes in patients with acute ischemic stroke (AIS). METHODS: In this double-blind phase 2b trial, patients with AIS aged 18-80 years with NIH Stroke Scale scores of 5-23 from 53 US and European sites were randomized 1:1:1 to receive a single dose of 300 or 600 mg IV natalizumab or placebo, with randomization stratified by treatment window (≤9 or >9 to ≤24 hours from patient's last known normal state). The primary endpoint was a composite measure of excellent outcome (modified Rankin Scale score ≤1 and Barthel Index score ≥95) at day 90 assessed in all patients receiving a full dose. Sample size was estimated from a Bayesian model; p values were not used for hypothesis testing. RESULTS: An excellent outcome was less likely with natalizumab than with placebo (natalizumab 300 or 600 mg odds ratio 0.60; 95% confidence interval 0.39-0.93). There was no effect modification by time to treatment or use of thrombolysis/thrombectomy. For natalizumab 300 mg, 600 mg, or placebo, there were no differences in incidence of adverse events (90.0%, 92.1%, and 92.3%, respectively), serious adverse events (25.6%, 32.6%, and 20.9%, respectively), or deaths (6.7%, 4.5%, and 5.5%, respectively). CONCLUSIONS: Natalizumab administered ≤24 hours after AIS did not improve patient outcomes. CLINICALTRIALSGOV IDENTIFIER: NCT02730455 CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that for patients with AIS, an excellent outcome was less likely in patients treated with natalizumab than with placebo.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Elkind MSV, Veltkamp R, Montaner J, et al. Natalizumab in acute ischemic stroke (ACTION II): A randomized, placebo-controlled trial. Neurology. 2020. PMID: 32591475. doi:10.1212/WNL.0000000000010038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。